Editorial: Diagnosis of GH deficiency in adults - How good do the criteria need to be?

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 2, 2002, Pages 473-476

  Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ADULT DISEASE; AGE; ARTHRALGIA; CARPAL TUNNEL SYNDROME; CHEMOLUMINESCENCE; DRUG EFFICACY; EDITORIAL; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; PRIORITY JOURNAL; PROVOCATION TEST; RADIOIMMUNOASSAY; TRANSSPHENOIDAL SURGERY; ADULT; ENDOCRINE DISEASE; NOTE;

ADULT; ENDOCRINE SYSTEM DISEASES; HUMAN GROWTH HORMONE; HUMANS;

EID: 0036172494     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.87.2.473     Document Type: Editorial

References (50)

1. Clinical aspects of growth hormone deficiency in adults
2. GH deficiency in adulthood and the effects of GH replacement. A review
3. Growth hormone therapy in adults and children
4. Optimizing GH therapy in adults and children
5. Diagnosis and management of growth hormone deficiency in adults
6. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults
7. Pretreatment IGF-1 level is the major determinant of GH dosage in adult GH deficiency
8. Route of estrogen administration helps to determine growth hormone (GH) replacement in GH-deficient adults
9. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency
10. Consensus. Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the Growth Hormone Research Society
11. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas
12. The clinical and endocrine outcome to transsphenoidal microsurgery of non-secreting pituitary adenomas
13. Anterior pituitary function in patients with nonfunctioning pituitary adenoma: Results of longitudinal follow-up
14. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas
15. Hypopituitarism following external radiotherapy for pituitary tumors in adults
16. Hypothalamic-pituitary dysfunction after radiation for brain tumors
17. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism
18. Diagnosis of growth hormone deficiency in adults
19. Assessment of GH status in adults with GH deficiency using serum growth hormone, serum insulin-like growth factor-I and urinary growth hormone excretion
20. GH deficiency in adults: An epidemiological approach
21. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency?
22. Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment
23. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3
24. Diagnosis of growth hormone deficiency in adults
25. Reproducibility of the insulin tolerance test (ITT) for assessment of growth hormone and cortisol secretion in normal and hypopituitary adult men
26. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: Comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretogogues
27. How many tests are required to diagnose growth hormone (GH) deficiency in adults?
28. Serum levels of insulin-like growth factor-I in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects
29. Evaluation of free insulin-like growth factor-I measurement on the diagnosis and follow-up treatment of growth hormone-deficient adult patients
30. Evaluation and application of a highly sensitive assay for serum growth hormone (GH) in the study of adult GH deficiency
31. Premature mortality due to cardiovascular disease in hypopituitarism
32. The effect of hypopituitarism on life expectancy
33. Increased cerebrovascular mortality in patients with hypopituitarism
34. Life expectancy following surgery for pituitary tumours
35. Association between premature mortality and hypopituitarism
36. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study
37. Incidence and late prognosis of Cushing's syndrome: A population-based study
38. The production rate of cortisol in mean
39. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
40. Incidence of cerebral infarction after radiotherapy for pituitary adenoma
41. Growth hormone and cardiovascular disease: An area in rapid growth
42. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom free hypopituitary adults
43. Increased arterial intima-media thickness in childhood onset growth hormone deficiency
44. Decrease in carotid intima-media thickness after one year GH treatment in adults with GH deficiency
45. Effect of GH replacement therapy on physical work capacity and cardiac and pulmonary function in patients with GHD acquired in adulthood
46. Improved cardiovascular risk factors and cardiac performance after 12 months of GH replacement in young adult patients with GH deficiency
47. Replacement treatment with biosynthetic GH in GHD hypopituitary adults
48. Effects of 7 years of GH replacement therapy in hypopituitary adults
49. Measures of submaximal aerobic performance evaluate and predict functional response to GH treatment in GHD adults
50. The "Quality of Life-Assessment of GHD in Adults" questionnaire: Can it be used to assess quality of life in hypopituitarism